Janux Therapeutics, Inc. (JANX) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$16.61

From 52W high−51.81%

Volume915058.00

Market cap$1.02B

P/E (TTM)—

P/S (TTM)42.6x

Div yield—

Key dataOct 19, 2026

Open

$16.61

From 52W high

−51.81%

Volume

915058.00

Market cap

$1.02B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.7x

P/E (TTM)

—

RSI (14)

45.7

MomentumView details →

1D Return

+1.39%

YTD Return

+21.63%

SummaryUpdated Jun 1, 2026

Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in La Jolla, California. The company went public in June 2021 and focuses on developing innovative cancer immunotherapies using its proprietary platform technologies. Janux specializes in creating next-generation T-cell engager therapies designed to harness the body's immune system to fight cancer more effectively than traditional treatments.

Ask drillr about Janux Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.7x

EV/Sales

3.1x

P/S (TTM)

42.6x

P/B (TTM)

1.1x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−427.47%

EBITDA Margin

−419.55%

ROE (TTM)

−11.06%

ROA (TTM)

−10.18%

Asset Turnover

0.02x

GrowthView details →

Revenue YoY

+5366.97%

EPS YoY

+8.33%

FCF YoY

+30.94%

Revenue CAGR 3Y

+5.11%

EPS CAGR 3Y

−42.97%

EBITDA YoY

+16.19%

MomentumView details →

1D Return

+1.39%

YTD Return

+21.63%

1Y Return

−37.63%

RSI (14)

45.7

vs 50D SMA

−4.03%

vs 200D SMA

+10.60%

Capital & dividendView details →

Debt/Equity

0.02x

Current Ratio

16.35x

Quick Ratio

16.35x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.35

EPS Surprise

−39.28%

Beats (12Q)

7/12

Next Q EPS Est

−$0.53

Avg Surprise (4Q)

1.54%

Rev Surprise

−46.17%

Financials snapshotView financials →

Revenue (TTM)

24.00M

Net Income (TTM)

−102.59M

Op. CF (TTM)

−41.25M

Next earningsNov 5, 2026 →

Latest newsMore news →

Janux Therapeutics reported a second-quarter net loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, and compared to a $0.55 loss per share in the same quarter last year.74d ago

Similar companies

NewAmsterdam Pharma Company N.V.NAMSW Replimune Group, Inc.REPL Maravai LifeSciences Holdings, Inc.MRVI Verastem, Inc.VSTM Ventyx Biosciences, Inc.VTYX Cloudbreak Pharma Inc.02592.HK Find similar companies →

Latest newsMore news →

Janux Therapeutics dosed the first patient in a Phase 1 clinical trial of JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer.36d ago Janux Therapeutics reported a second-quarter net loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, and compared to a $0.55 loss per share in the same quarter last year.74d ago